Abiopharma

🔍 Moore Duncan (Executive)

Company: ASP Isotopes Inc. (ASPI)

Report Date: 2025-11-12-05:00

Detailed Transactions and Holdings:

• Acquired 25,469 shares of Common Stock (Direct)
  Date: 2025-11-12-05:00 | Code: A | equity_swap_involved: false | shares_owned_after: 1,020,022.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 36,548 shares of Common Stock (Direct)
  Date: 2025-12-18-05:00 | Code: A | equity_swap_involved: false | shares_owned_after: 1,056,570.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 11,642 shares of Common Stock at $5.205 per share (Direct)
  Date: 2026-04-16-05:00 | Code: S | equity_swap_involved: false | shares_owned_after: 1,044,928.00 | transaction_form_type: 4 | Footnotes: F3, F4

Footnotes:

• F1: Award of shares of restricted stock in connection with the reporting person's service as an independent director of ASP Isotopes Inc. on the QLE Structuring and Strategic Transactions Committee.
• F2: 2025 annual award of shares of restricted stock in connection with the reporting person's service as an independent director of ASP Isotopes Inc.
• F3: The sale of shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 31, 2025 and includes an amount for the purpose of satisfying the reporting person's income tax liabilities resulting from the vesting of a previously granted restricted stock award pursuant to an issuer equity incentive plan.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.055 to $5.52, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote 2.